1887

Chapter 102 : Cardiovascular Diseases

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Cardiovascular Diseases, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH102-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH102-2.gif

Abstract:

Acute myocardial injury (AMI) most often results from a lack of sufficient blood supply to the myocardium. When patients present with symptoms of chest pain, rapid diagnosis of potential AMI and characterization of the extent of cardiac injury are essential for delivering appropriate treatment, e.g., intervention with thrombolytic therapy or angioplasty. Such interventions are aimed at minimizing the risk of (further) cardiac injury and death. Distinguishing patients with unstable angina from those with AMI is necessary to triage whether patients may be managed in the outpatient setting versus inpatient admission and immediate intervention. Serologic measurements of soluble biomarkers released during myocyte necrosis are used in conjunction with electrocardiograms and with more sophisticated imaging techniques like echocardiography and perfusion scintigraphy. Serum biomarkers have the greater advantage of detecting recent myocardial injury, which is not easily distinguishable by cardiac imaging techniques in patients with clinical evidence of preexisting heart disease (Table 1).

Citation: Maier C, Burek C, Rose N, Ansari A. 2016. Cardiovascular Diseases, p 975-982. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch102
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555818722.ch102
1. Gotlieb AI, Freeman MR, Salerno TA, Lichtenstein SV, Armstrong PW. 1991. Ultrastructural studies of unstable angina in living man. Mod Pathol 4:7580.[PubMed]
2. Levin ER, Gardner DG, Samson WK. 1998. Natriuretic peptides. N Engl J Med 339:321328.[CrossRef].[PubMed]
3. Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. 2003. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 49:13311336.[PubMed].[CrossRef]
4. McCord J, Nowak RM, McCullough PA, Foreback C, Borzak S, Tokarski G, Tomlanovich MC, Jacobsen G, Weaver WD. 2001. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 104:14831488.[PubMed].[CrossRef]
5. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. 2007. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115:21032110.[CrossRef].[PubMed]
6. Nickel CH, Bingisser R, Morgenthaler NG. 2012. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 10:7. doi:10.1186/1741-7015-10-7.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1186/1741-7015-10-7
7. Seino Y, Ogata K, Takano T, Ishii J, Hishida H, Morita H, Takeshita H, Takagi Y, Sugiyama H, Tanaka T, Kitaura Y. 2003. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. Am J Med 115:185190.[PubMed].[CrossRef]
8. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. 2002. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol 40:238244.[PubMed].[CrossRef]
9. Kilcullen N, Viswanathan K, Das R, Morrell C, Farrin A, Barth JH, Hall AS EMMACE-2 Investigators. 2007. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol 50:20612067.[CrossRef].[PubMed]
10. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G. 2003. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33:648656.[PubMed].[CrossRef]
11. Mann DL. 2003. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65:81101.[CrossRef].[PubMed]
12. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. 2002. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4:439444.[PubMed].[CrossRef]
13. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T. 2004. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 6:4145.[CrossRef].[PubMed]
14. Feuerstein GZ, Rozanski D. 2000. G proteins and heart failure: is Gαq a novel target for heart failure? Circ Res 87:10851086.[PubMed].[CrossRef]
15. Wettschureck N, Rütten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S. 2001. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nat Med 7:12361240.[CrossRef].[PubMed]
16. Suzuki T, Yamazaki T, Yazaki Y. 2001. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 51:489494.[PubMed].[CrossRef]
17. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. 2003. Natriuretic peptides (NPs): automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 49:15521554.[PubMed].[CrossRef]
18. Li YY, McTiernan CF, Feldman AM. 2000. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46:214224.[PubMed].[CrossRef]
19. Upadhya B, Kontos JL, Ardeshirpour F, Pye J, Boucher WS, Theoharides TC, Dehmer GJ, Deliargyris EN. 2004. Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. J Card Fail 10:3135.[PubMed].[CrossRef]
20. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L. 1999. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83:376382.[PubMed].[CrossRef]
21. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M. 1998. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31:391398.[PubMed].[CrossRef]
22. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Frøland SS, Fowler M. 1999. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34:20612067.[PubMed].[CrossRef]
23. Wollert KC, Drexler H. 2001. The role of interleukin-6 in the failing heart. Heart Fail Rev 6:95103.[PubMed].[CrossRef]
24. Noutsias M, Hohmann C, Pauschinger M, Schwimmbeck PL, Ostermann K, Rode U, Yacoub MH, Kühl U, Schultheiss HP. 2003. sICAM-1 correlates with myocardial ICAM-1 expression in dilated cardiomyopathy. Int J Cardiol 91:153161.[PubMed].[CrossRef]
25. Alcalai R, Seidman JG, Seidman CE. 2008. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 19:104110.[CrossRef].[PubMed]
26. Keren A, Syrris P, McKenna WJ. 2008. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 5:158168.[CrossRef].[PubMed]
27. Watkins H, Ashrafian H, McKenna WJ. 2008. The genetics of hypertrophic cardiomyopathy: teare redux. Heart 94:12641268.[CrossRef].[PubMed]
28. Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, Ommen SR, Theis JL, Vaubel RA, Re F, Armentano C, Poggesi C, Torricelli F, Cecchi F. 2008. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 83:630638.[CrossRef].[PubMed]
29. Wang L, Seidman JG, Seidman CE. 2010. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 152:513520, W181.[CrossRef].[PubMed]
30. Petretta M, Pirozzi F, Sasso L, Paglia A, Bonaduce D. 2011. Review and metaanalysis of the frequency of familial dilated cardiomyopathy. Am J Cardiol 108:11711176.[CrossRef].[PubMed]
31. McNally EM, Golbus JR, Puckelwartz MJ. 2013. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 123:1926.[CrossRef].[PubMed]
32. Gahl WA, Markello TC, Toro C, Fajardo KF, Sincan M, Gill F, Carlson-Donohoe H, Gropman A, Pierson TM, Golas G, Wolfe L, Groden C, Godfrey R, Nehrebecky M, Wahl C, Landis DM, Yang S, Madeo A, Mullikin JC, Boerkoel CF, Tifft CJ, Adams D. 2012. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet Med 14:5159.[CrossRef].[PubMed]
33. LeWinter MM, Wu Y, Labeit S, Granzier H. 2007. Cardiac titin: structure, functions and role in disease. Clin Chim Acta 375:19.[CrossRef].[PubMed]
34. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE. 2012. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366:619628.[CrossRef].[PubMed]
35. Norton N, Robertson PD, Rieder MJ, Züchner S, Rampersaud E, Martin E, Li D, Nickerson DA, Hershberger RE National Heart, Lung and Blood Institute GO Exome Sequencing Project. 2012. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet 5:167174.[CrossRef].[PubMed]
36. Mason JW. 2003. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res 60:510.[PubMed].[CrossRef]
37. Aretz HT. 1987. Myocarditis: the Dallas criteria. Hum Pathol 18:619624.[PubMed].[CrossRef]
38. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, Olsen EG, Schoen FJ. 1987. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1:314.[PubMed]
39. Mason JW. 1996. Immunopathogenesis and treatment of myocarditis: the United States Myocarditis Treatment Trial. J Card Fail 2(Suppl):S173S177.[PubMed].[CrossRef]
40. Fett JD, McTiernan CF. 2011. Towards a unifying hypothesis for the pathogenesis of peripartum cardiomyopathy. Int J Cardiol 153:13.[CrossRef].[PubMed]
41. Harper MA, Meyer RE, Berg CJ. 2012. Peripartum cardiomyopathy: population-based birth prevalence and 7-year mortality. Obstet Gynecol 120:10131019.[CrossRef].[PubMed]
42. Fett JD, Ansari AA. 2010. Inflammatory markers and cytokines in peripartum cardiomyopathy: a delicate balance. Expert Opin Ther Targets 14:895898.[CrossRef].[PubMed]
43. McTiernan C, Hanley-Yanez K, Pisarcik JE, Morel PA, Cooper LT, Elkayam E, Fett JD, McNamara DM. 2011. Activation of cellular immunity in peripartum cardiomyopathy: results of the multicenter IPAC Registry. Circulation 124:A14173. https://circ.ahajournals.org/cgi/content/meeting_abstract/124/21_MeetingAbstracts/A14173.
44. Fett JD. 2013. Earlier detection can help avoid many serious complications of peripartum cardiomyopathy. Future Cardiol 9:809816.[CrossRef].[PubMed]
45. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H. 2007. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589600.[CrossRef].[PubMed]
46. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, McMurray J, Yamac H, Labidi S, Struman I, Hilfiker-Kleiner D. 2010. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121:14651473.[CrossRef].[PubMed]
47. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z. 2012. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485:333338.[CrossRef].[PubMed]
48. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. 2012. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125:911919.[CrossRef].[PubMed]
49. Fett JD, Sannon H, Thélisma E, Sprunger T, Suresh V. 2009. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynaecol Obstet 104:125127.[CrossRef].[PubMed]
50. Huang GY, Zhang LY, Long-Le MA, Wang LX. 2012. Clinical characteristics and risk factors for peripartum cardiomyopathy. Afr Health Sci 12:2631.[PubMed]
51. Sliwa K, Förster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. 2006. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 27:441446.[CrossRef].[PubMed]
52. Warraich RS, Sliwa K, Damasceno A, Carraway R, Sundrom B, Arif G, Essop R, Ansari A, Fett J, Yacoub M. 2005. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J 150:263269.[CrossRef].[PubMed]
53. Mascaro-Blanco A, Alvarez K, Yu X, Lindenfeld J, Olansky L, Lyons T, Duvall D, Heuser JS, Gosmanova A, Rubenstein CJ, Cooper LT, Kem DC, Cunningham MW. 2008. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity 41:442453.[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Serum biomarkers used for diagnosis of AMI

Citation: Maier C, Burek C, Rose N, Ansari A. 2016. Cardiovascular Diseases, p 975-982. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch102
Generic image for table
TABLE 2

Serum biomarkers for CMI

Citation: Maier C, Burek C, Rose N, Ansari A. 2016. Cardiovascular Diseases, p 975-982. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch102
Generic image for table
TABLE 3

Infectious and noninfectious etiologies of inflammatory cardiomyopathy

Citation: Maier C, Burek C, Rose N, Ansari A. 2016. Cardiovascular Diseases, p 975-982. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch102
Generic image for table
TABLE 4

Autoantibodies detected in inflammatory cardiomyopathies

Citation: Maier C, Burek C, Rose N, Ansari A. 2016. Cardiovascular Diseases, p 975-982. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch102
Generic image for table
TABLE 5

Clinical immunological assays for detection and characterization of inflammatory heart disease

Citation: Maier C, Burek C, Rose N, Ansari A. 2016. Cardiovascular Diseases, p 975-982. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch102

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error